Literature DB >> 31274655

Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer.

Giampaolo Perri1, Laura Prakash1, Huamin Wang2, Priya Bhosale3, Gauri R Varadhachary4, Robert Wolff4, David Fogelman4, Michael Overman4, Shubham Pant4, Milind Javle4, Eugene Koay5, Joseph Herman5, Michael Kim1, Naruhiko Ikoma1, Ching-Wei Tzeng1, Jeffrey E Lee1, Matthew H G Katz1.   

Abstract

OBJECTIVE: We sought to identify potential radiologic and serologic markers of pancreatic tumor response to therapy, using pathologic major response (pMR) as the objective endpoint.
BACKGROUND: We previously demonstrated that a pMR to preoperative therapy, defined as detection of <5% viable cancer cells in the surgical specimen on histopathological analysis, is an important prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC).
METHODS: Pretreatment and posttreatment computed tomography scans of consecutive patients who received preoperative chemotherapy and/or (chemo)radiation before pancreatectomy for PDAC between January 2010 and December 2018 were rereviewed. Response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, other radiographic changes in tumor size and anatomic extent, and posttreatment CA 19-9 levels were compared between patients who did and did not have a pMR on final histopathologic analysis of their surgical specimens.
RESULTS: A total of 290 patients with localized PDAC underwent pancreatectomy between 2010 and 2018 after receiving preoperative chemotherapy (n = 36; 12%), (chemo)radiation (n = 87; 30%), or both (n = 167; 58%). Among them, 28 (10%) experienced pMR, including 9 (3.1%) who experienced pathologic complete response. On multivariable logistic regression, low posttreatment CA 19-9 level, RECIST partial response, and reduction in tumor volume were confirmed to be independently associated with pMR (P < 0.01).
CONCLUSIONS: We identified serologic and radiographic indicators of pMR that could help inform the delivery of preoperative therapy to patients with PDAC.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 31274655      PMCID: PMC7703852          DOI: 10.1097/SLA.0000000000003442

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  29 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.

Authors:  Qing Zhao; Asif Rashid; Yun Gong; Matthew H Katz; Jeffrey E Lee; Robert Wolf; Aparna Balachandran; Gauri R Varadhachary; Peter W Pisters; Hua Wang; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Ann Diagn Pathol       Date:  2011-11-03       Impact factor: 2.090

3.  Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.

Authors:  Giovanni Marchegiani; Valentina Todaro; Enrico Boninsegna; Riccardo Negrelli; Binit Sureka; Debora Bonamini; Roberto Salvia; Riccardo Manfredi; Roberto Pozzi Mucelli; Claudio Bassi
Journal:  Eur Radiol       Date:  2018-04-20       Impact factor: 5.315

4.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

5.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Gauri R Varadhachary; Robert A Wolff; Hua Wang; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Christopher Crane; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Cancer       Date:  2011-10-25       Impact factor: 6.860

6.  Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Authors:  Jordan M Cloyd; Huamin Wang; Michael E Egger; Ching-Wei D Tzeng; Laura R Prakash; Anirban Maitra; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Michael J Overman; Eugene J Koay; Prajnan Das; Joseph M Herman; Michael P Kim; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

7.  Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.

Authors:  Matthew H G Katz; Gauri R Varadhachary; Jason B Fleming; Robert A Wolff; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Charlotte C Sun; Huamin Wang; Christopher H Crane; Jeffrey H Lee; Eric P Tamm; James L Abbruzzese; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2010-02-17       Impact factor: 5.344

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.

Authors:  Ching-Wei D Tzeng; Daniel E Abbott; Scott B Cantor; Jason B Fleming; Jeffrey E Lee; Peter W T Pisters; Gauri R Varadhachary; James L Abbruzzese; Robert A Wolff; Syed A Ahmad; Matthew H G Katz
Journal:  Ann Surg Oncol       Date:  2013-02-14       Impact factor: 5.344

10.  Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.

Authors:  Ahmed M Amer; Mohamed Zaid; Baishali Chaudhury; Dalia Elganainy; Yeonju Lee; Christopher T Wilke; Jordan Cloyd; Huamin Wang; Anirban Maitra; Robert A Wolff; Gauri Varadhachary; Michael J Overman; Jeffery E Lee; Jason B Fleming; Ching Wei Tzeng; Matthew H Katz; Emma B Holliday; Sunil Krishnan; Bruce D Minsky; Joseph M Herman; Cullen M Taniguchi; Prajnan Das; Christopher H Crane; Ott Le; Priya Bhosale; Eric P Tamm; Eugene J Koay
Journal:  Cancer       Date:  2018-01-25       Impact factor: 6.860

View more
  14 in total

1.  Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).

Authors:  Ken-Ichi Okada; Manabu Kawai; Seiko Hirono; Fumiyoshi Kojima; Kensuke Tanioka; Masaki Terada; Motoki Miyazawa; Yuji Kitahata; Yoshifumi Iwahashi; Masaki Ueno; Shinya Hayami; Shin-Ichi Murata; Toshio Shimokawa; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2020-01-28       Impact factor: 3.445

2.  CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Laura Maggino; Giuseppe Malleo; Stefano Crippa; Massimo Falconi; Roberto Salvia; Giulio Belfiori; Sara Nobile; Giulia Gasparini; Gabriella Lionetto; Claudio Luchini; Paola Mattiolo; Marco Schiavo-Lena; Claudio Doglioni; Aldo Scarpa; Claudio Bassi
Journal:  Ann Surg Oncol       Date:  2022-10-13       Impact factor: 4.339

3.  Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.

Authors:  Timothy P DiPeri; Timothy E Newhook; Laura R Prakash; Naruhiko Ikoma; Jessica E Maxwell; Michael P Kim; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng
Journal:  J Surg Oncol       Date:  2022-06-20       Impact factor: 2.885

Review 4.  Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.

Authors:  Mehran Taherian; Huamin Wang
Journal:  Chin Clin Oncol       Date:  2022-06-16

5.  ASO Author Reflections: The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.

Authors:  Giampaolo Perri; Matthew H G Katz
Journal:  Ann Surg Oncol       Date:  2020-05-01       Impact factor: 5.344

6.  An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Zengyu Feng; Kexian Li; Jianyao Lou; Yulian Wu; Chenghong Peng
Journal:  Front Cell Dev Biol       Date:  2021-04-30

7.  Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma.

Authors:  Patrick M McCarthy; Matthew J Rendo; Matthew D Uy; Alexandra M Adams; Anne E O'Shea; Daniel William Nelson; Joshua L Fenderson; Katherine M Cebe; Robert W Krell; Guy T Clifton; George E Peoples; Timothy J Vreeland
Journal:  Onco Targets Ther       Date:  2021-06-01       Impact factor: 4.147

8.  Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.

Authors:  Giampaolo Perri; Laura Prakash; Wei Qiao; Gauri R Varadhachary; Robert Wolff; David Fogelman; Michael Overman; Shubham Pant; Milind Javle; Eugene J Koay; Joseph Herman; Michael Kim; Naruhiko Ikoma; Ching-Wei Tzeng; Jeffrey E Lee; Matthew H G Katz
Journal:  JAMA Surg       Date:  2020-09-01       Impact factor: 14.766

9.  Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.

Authors:  Dongguang Wei; Mohamed M Zaid; Matthew H Katz; Laura R Prakash; Michael Kim; Ching-Wei D Tzeng; Jeffrey E Lee; Anshuman Agrawal; Asif Rashid; Hua Wang; Gauri Varadhachary; Robert A Wolff; Eric P Tamm; Priya R Bhosale; Anirban Maitra; Eugene J Koay; Huamin Wang
Journal:  Pancreatology       Date:  2020-11-14       Impact factor: 3.996

10.  The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.

Authors:  Giampaolo Perri; Laura Prakash; Giuseppe Malleo; Andrea Caravati; Gauri R Varadhachary; David Fogelman; Shubham Pant; Eugene J Koay; Joseph Herman; Laura Maggino; Michele Milella; Michael Kim; Naruhiko Ikoma; Ching-Wei Tzeng; Roberto Salvia; Jeffrey E Lee; Claudio Bassi; Matthew H G Katz
Journal:  Ann Surg Oncol       Date:  2020-04-07       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.